Brief: Endo International Executes Agreement With TLC To Commercialize Phase 3 Orthopedic Product For Treatment Of Osteoarthritis Knee Pain
13/06/2022 11:39
June 13 (Reuters) - Endo International PLC ENDP.O :
* ENDO EXECUTES AGREEMENT WITH TLC TO COMMERCIALIZE PHASE 3
ORTHOPEDIC PRODUCT FOR THE TREATMENT OF OSTEOARTHRITIS KNEE PAIN
* ENDO INTERNATIONAL PLC - ENDO VENTURES LIMITED (EVL) HAS
EXECUTED AN AGREEMENT WITH TAIWAN LIPOSOME COMPANY, LTD.
* ENDO INTERNATIONAL PLC - UNDER TERMS OF AGREEMENT, TLC
WILL
PRIMARILY BE RESPONSIBLE FOR DEVELOPMENT OF PRODUCT
* ENDO INTERNATIONAL PLC - UPFRONT PAYMENT OF $30 MILLION
WILL BE
EXPENSED IN Q2 AS ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT
* ENDO INTERNATIONAL PLC - THIS EXPENSE WAS NOT REFLECTED IN
ENDO'S Q2 2022 FINANCIAL GUIDANCE PROVIDED ON MAY 5, 2022
* ENDO INTERNATIONAL PLC - ENDO CURRENTLY EXPECTS TO LAUNCH
DIFFERENTIATED BRANDED PRODUCT IN UNITED STATES IN 2025
Source text for Eikon: ID:nPn4fhbHKa
Further company coverage: ENDP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes